Lowest Price Guaranteed From USD 4,799
Published
July 2023
Pages
190
View Count
11506
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The global exosome therapy market is estimated to be USD 32 million in 2022 and is anticipated to grow at a compounded annual growth rate (CAGR) of 41.1% during the forecast period. In recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse indications, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. Currently, both industry and non-industry players are attempting to develop exosome therapeutics for disease management, some of which are already in clinical trials. Moreover, post the onset of the COVID-19 pandemic, there has been a steady increase in the investigational new drug (IND) applications filed for exosome therapy. In a recent review of more than 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use, the exosomes demonstrated benefits in more than 70% of studies.
The Exosome Therapy Market, Distribution by Type of Therapeutic (Allogeneic and Autologous), Target Indication (Degenerative Meniscal Injury, Dystrophic Epidermolysis Bullosa, Fistula Perianal and Retinitis Pigmentosa), Therapeutic Area (Dermatological Disorders, Musculoskeletal Disorders, Ophthalmic Diseases and Rectal Disorders), Route of Administration (Fistula Tract, Intra-articular and Intra-ocular) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2040 report features an extensive study of the current market landscape, market size and future outlook for the companies involved in developing exosome therapy. The market report answers many key questions related to this industry.
The exosome therapy market is presently growing at a significant pace among the dynamic sectors of pharmaceutical industry. At present, the pipeline features close to 120 therapeutic candidates, and this number is anticipated to grow further in the forecast period. More than 40% of the total number of drugs are in clinical stage of development. Of the total candidates, seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute), SF-MSC-EX (Osmangazi University), are currently being evaluated in the advanced clinical stages of development.
Further, around 30% of the exosome therapeutics are being developed for treatment of cancer. Exosome based therapy for cancer is a novel approach and the drugs are currently in early stages of development. Breast cancer, lung cancer, melanoma and colon cancer are amongst some of the oncological indications where exosomes are being tested as delivery vehicles for targeted therapy.
Over time, more than 60 pharmaceutical companies and academic / research institutes have undertaken various initiatives to develop effective exosome therapies against multiple target indications. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the efforts in research and development of various pipeline candidates, over the past decade. In one such agreement signed in June 2022, Coya Therapeutics in licensed an exosome engineering technology from Carnegie Mellon University. The company gained worldwide rights to the exosome polymer hybrid technology that allows targeted delivery of the exosomes carrying drug of interest. Their first exosome therapy, COYA 206, based on this in licensed technology is currently in early research.
In the last five years, capital investments worth around USD 500 million have been made by strategic investors for the research and development of exosome therapeutics. These funds have been raised through 35 number of instances, equating to an average of USD 16 million per funding round. In the most recent instance, Mantra Bio announced a USD 9 million Series A-2 round in January 2023. The company is developing targeted exosome therapeutics for ophthalmology and infectious disease.
Despite the numerous benefits offered by exosome therapies, developers often face concerns related to the weak therapy preparations, bacterial infections, and contamination with non-exosomal components. Additionally, the heterogeneous nature of such extracellular vesicles (EVs) is one of the major challenges faced during the quantification and characterization of the required EVs from a diverse population of cells. In order to mitigate the aforementioned challenges, novel technologies are being adopted by several stakeholders.
The exosome therapeutics market is currently valued at USD 32 million in 2022. The market is projected to grow at a CAGR of more than 40%, with anticipated release of a number of therapies during the forecast period. In terms of route of administration, the market is likely to be driven by exosome therapeutics designed for intra-ocular administration. Further, in terms of therapeutic area, majority share of the revenues is expected to be generated by ophthalmic diseases. Specifically, in terms of geography, the exosome therapeutics market in Asia-Pacific is likely to grow at a significant pace, in the long term.
The factors contributing to the growth of exosome therapeutics market include increasing disease burden, rise in research and development activities for exosome therapeutics, and government funding for the production of exosome therapy. Moreover, the growth potential in the emerging economies will bolster the exosome therapeutics market growth during the forecast period.
In March 2023, one of the well-known companies in the exosome therapy industry, Codiak BioSciences filed for bankruptcy. The company had two clinical stage exosome therapy and a preclinical stage molecule targeting cancer. According to Codiak BioSciences, the company did not have sufficient funds to carry forward the development of the molecules. This instance also reflects upon the smaller amount of funds that the developers are able to raise, which may not be sufficient once the pipeline moves into clinical trials.
Additionally, seven exosome therapeutics under development against various indications, primarily cancer, have been withdrawn due to limited or no patient enrollment, non-adherence to dosage regimen and financial constraints. In absence of availability of sufficient funds, the exosome therapy market is likely to witness events that can restrain the market growth.
The key companies engaged in this market (which have also been capture in this report) include Cellular Biomedicine Group, Coya Therapeutics, Curexsys, EV Therapeutics, Evox Therapeutics, ExoCoBio, ILIAS Biologics, Rion and SHIFTBIO. This market report includes an easily searchable excel database of all the companies and academic institutes developing exosome therapy.
Several recent developments have taken place in the field of exosome therapy market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The market report presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this industry, across different geographies as defined in the below table:
| Key Report Attributes | Details | |
|
Forecast Period |
2022-2040 |
|
|
Base Year |
2021 | |
|
Market Size 2022 |
$32 million | |
|
CAGR |
41% | |
|
Type of Exosome Therapeutics |
Allogenic, Autologous | |
|
Target Disease Indications |
Degenerative Meniscal Injury, Dystrophic Epidermolysis Bullosa, Fistula Perianal, Retinitis Pigmentosa |
|
|
Therapeutic Area |
Dermatological Disorders, Musculoskeletal Disorders, Ophthalmic Disorders | |
| Type of Formulation | Liquid, Aerosol | |
| Route of Administration |
Fistula Tract, Intra-articular, Intra-ocular |
|
| Geographical Regions |
North America, Europe, Asia-Pacific and Rest of the World |
|
| Key Companies Profiled | Coya Therapeutics, Evox Therapeutics, Curexsys, EV Therapeutics, SHIFTBIO | |
| Customizatiion Scope | 15% Free Customization Option | |
| PowerpPoint Presentation (Complimentary) | Available | |
| Excel Data Packs | Market Landscape Analysis, Company Competitiveness Analysis, Patent Analysis, Recent Developments, Market Forecast and Opportunity Analysis | |
Amongst other elements the research report includes:
One of the key objectives of the market report was to identify the primary growth drivers and estimate the future growth opportunity associated with exosome therapy market in the mid to long term. Based on various parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the forecast period 2029-2040. Our year wise projections of the current and forecasted opportunity within the exosome therapeutics market have further been segmented across type of therapeutic (allogeneic and autologous), target disease indication(s) (degenerative meniscal injury, dystrophic epidermolysis bullosa, fistula perianal and retinitis pigmentosa), therapeutic area (dermatological disorders, musculoskeletal disorders, ophthalmic diseases and rectal disorders), route of administration (fistula tract, intra-articular and intra-ocular), geography (North America, Europe and Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report were influenced by discussions held with several stakeholders in exosome industry. The research report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Exosomes
3.1.1. Types of Extracellular Vesicles
3.1.1. Potential Sources of Exosomes
3.2. Exosome Biogenesis
3.2.1. Exosome Formation and Development Process
3.2.2. Secretion of Exosomes
3.3. Applications of Exosomes
3.4. Mechanism of Exosome Therapy
3.4.1. Exosome Drug Therapy
3.4.2. Exosome RNAi Therapy
3.4.3. Exosome Immunotherapy
3.5. Advantages of Exosome Therapy
3.6. Risks and Future Perspectives Associated with Exosome Therapeutics
4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Exosome Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Technology Platform
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Derived Source
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Phase of Development and Therapeutic Area
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Route of Administration
4.2.10 Analysis by Area of Application
4.2.11. Analysis by Type of Therapy
4.2.12. Analysis by Dosing Frequency
4.2.13. Analysis by Type of Therapy (By Method of Composition)
4.2.14. Analysis by Line of Treatment
4.3. Exosome Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
5. EXOSOME THERAPY : COMPANY PROFILES
5.1. Coya Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Developments and Future Outlook
5.2. Evox Therapeutics
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Curexsys
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. EV Therapeutics
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. SHIFTBIO
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook
6. EXOSOME THERAPY: DRUG PROFILES
6.1. AEGLE Therapeutics
6.1.1. Company Overview
6.1.2. AGLE-102: Product Portfolio
6.1.2.1. AGLE-102: Clinical Trial Information
6.1.3. Recent Developments and Future Outlook
6.2. AVEM Healthcare
6.2.1. Company Overview
6.2.2. Ardoxso: Product Portfolio
6.2.2.1. Ardoxso: Clinical Trial Information
6.2.3. Recent Developments and Future Outlook
6.3. Cellular Biomedicine Group
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. haMPC-Exos: Product Portfolio
6.3.3.1. haMPC-Exos: Clinical Trial Information
6.3.4. hMSC-Exos: Product Portfolio
6.3.4.1. hMSC-Exos: Clinical Trial Information
6.3.5. Undisclosed Drug 1: Product Portfolio
6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
6.3.6. Recent Developments and Future Outlook
6.4. OBCTCD24
6.4.1. Company Overview
6.4.2. CovenD24: Product Portfolio
6.4.2.1. CovenD24: Clinical Trial Information
6.4.3. Recent Developments and Future Outlook
6.5. ReNeuron
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Undisclosed Drug 1: Product Portfolio
6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
6.5.4. Recent Developments and Future Outlook
6.6. Stem Cell Medicine
6.6.1. Company Overview
6.6.2. Undisclosed Drug 1: Product Portfolio
6.6.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Exosome Therapeutics: List of Clinical Trials
7.2.1. Analysis by Trial Status
7.2.2. Analysis by Trial Registration Year
7.2.3. Analysis by Sponsor / Collaborator
7.2.4. Analysis by Trial Registration Year and Type of Study
7.2.5. Analysis by Trial Registration Year and Trial Status
7.2.6. Analysis by Annual Number of Patients Enrolled
7.2.7. Analysis by Study Design
7.2.8. Analysis by Age Category
7.2.9. Analysis by Phase of Development and Trial Status
7.2.10. Analysis by Phase of Development and Patients Enrolled
7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials
7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.2.13. Analysis by Trial Location
7.2.14. Analysis by Trial Status and Geography
7.2.15. Analysis by Trial Status, Patients Enrolled and Geography
8. ACADEMIC GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Exosome Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded per Year
8.5. Analysis by Type of Funding Institute Center
8.6. Analysis by Support Period
8.7. Analysis by Purpose of Grant
8.8. Word Cloud Analysis: Emerging Focus Area
8.9. Analysis by Grant Activity Code
8.10. Analysis by Location of Recipient Organizations
8.11. Popular Recipient Organizations: Analysis by Number of Grants
8.12. Popular Recipient Organizations: Analysis by Amount Awarded
8.13. Analysis by Type of Recipient Organization
8.14. Analysis by Study Section
8.15. Analysis by Type of Grant Application
8.16. Analysis by Funding Institute Center and Support Year
9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Region
9.3.5. Most Active Organizers: Analysis by Number of Events
9.3.6. Most Active Speakers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Exosome Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Company and Type of Partnership
10.3.5. Analysis by Type of Technology Platform
10.3.6. Analysis by Type of Partner
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Word Cloud Analysis: Emerging Focus Areas
10.3.9. Analysis by Target Disease Indication(s)
10.3.10. Analysis by Therapeutic Area
10.3.11. Analysis by Therapeutic Area and Type of Partnership
10.3.12. Regional Distribution of Partnerships
10.3.13. Distribution by Geography
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Type of Funding
11.3. Exosome Therapeutics: List of Funding Instances
11.4. Analysis by Year of Funding
11.5. Analysis by Amount Invested
11.6. Analysis by Type of Funding
11.7. Analysis by Type of Funding and Amount Invested
11.8. Analysis by Purpose of Funding
11.9. Analysis by Target Disease Indication(s)
11.10. Analysis by Therapeutic Area
11.11. Most Active Players: Analysis by Number of Funding Instances
11.12. Most Active Players: Analysis by Amount Raised
11.13. Active Investors: Analysis by Number of Funding Instances
11.14. Distribution by Geography
11.15. Summary of Funding Activity
12. START-UP HEALTH INDEXING
12.1. Analysis Methodology and Key Parameters
12.2. Analysis by Pipeline Strength
12.3. Analysis by Pipeline Maturity
12.4. Analysis by Indication Diversity
12.5. Analysis by Number of Partnerships
12.6. Analysis by Financial Support
12.7. Start-up Health Indexing: Roots Analysis Perspective
12.8. Most Active Start-ups
13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING COMPANIES
13.1. Chapter Overview
13.2. Exosome Development and Manufacturing Companies Landscape
13.2.1. Analysis by Year of Establishment
13.2.2. Analysis by Company Size
13.2.3. Analysis by Location of Headquarters
13.2.4. Analysis by Location of Headquarters and Company Size
13.3. Analysis by Type of Service(s) Offered
13.3.1. Analysis by Method of Isolation
13.3.2. Analysis by Method of Purification
13.3.3. Analysis by Method of Characterization
13.3.4. Analysis by Method of Exosome Manufacturing
13.3.5. Analysis by Scale of Operation
13.3.6. Analysis by Scalability
14. DRUG FAILURE ANALYSIS
14.1. Methodology and Key Parameters
14.2. Exosome Therapeutics: List of Failed Drug Candidates
14.2.1. Analysis by Trial Start and Discontinuation Year
14.2.2. Analysis by Trial Status of Discontinuation
14.2.3. Analysis by Target Disease Indication(s)
14.2.4. Analysis by Route of Administration
14.2.5. Analysis by Type of Sponsor
14.2.6. Analysis by Reasons for Drug Failure
14.2.7. Word Cloud Analysis: Emerging Focus Area
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Forecast Methodology and Key Assumptions
15.2. Global Exosome Therapy Market, 2029-2040
15.2.1. Exosome Therapy Market for Allogeneic Therapy, 2029-2040 (USD Million)
15.2.2. Exosome Therapy Market for Autologous Therapy, 2029-2040 (USD Million)
15.2.3. Exosome Therapy Market for Degenerative Meniscal Injury, 2031-2040 (USD Million)
15.2.4. Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
15.2.5. Exosome Therapy Market for Fistula Perianal, 2029-2040 (USD Million)
15.2.6. Exosome Therapy Market for Retinitis Pigmentosa, 2029-2040 (USD Million)
15.2.7. Exosome Therapy Market for Dermatological Disorders, 2030-2040 (USD Million)
15.2.8. Exosome Therapy Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
15.2.9. Exosome Therapy Market for Ophthalmic Disorders, 2029-2040 (USD Million)
15.2.10. Exosome Therapy Market for Rectal Disorders, 2029-2040 (USD Million)
15.2.11. Fistula Tract Exosome Therapy Market, 2029-2040 (USD Million)
15.2.12. Intra-articular Exosome Therapy Market, 2031-2040 (USD Million)
15.2.13. Intra-ocular Exosome Therapy Market, 2029-2040 (USD Million)
15.2.14. Exosome Therapy Market Geographical Distribution, 2029-2040 (USD Million)
15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million)
15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million)
16. EXECUTIVE INSIGHTS
16.1. Capricor Therapeutics
16.1.1. Company Snapshot
16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer
16.2. Exogenus Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager
16.3. ILIAS Biologics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Soonho Song, Chief Business Officer
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Types of Extracellular Vesicles
Figure 3.1 Potential Sources of Exosomes
Figure 3.2 Secretion of Exosomes
Figure 3.3 Mechanism of Exosome Therapy
Figure 4.1 Exosome Therapeutics: Distribution by Phase of Development
Figure 4.2 Exosome Therapeutics: Distribution by Technology Platform
Figure 4.3 Exosome Therapeutics: Distribution by Type of Payload
Figure 4.4 Exosome Therapeutics: Distribution by Derived Source
Figure 4.5 Exosome Therapeutics: Distribution by Target Disease Indication(s)
Figure 4.6 Exosome Therapeutics: Distribution by Therapeutic Area
Figure 4.7 Exosome Therapeutics: Distribution by Phase of Development and Therapeutic Area
Figure 4.8 Exosome Therapeutics: Distribution by Therapeutic Area and Route of Administration
Figure 4.9 Exosome Therapeutics: Distribution by Route of Administration
Figure 4.10 Exosome Therapeutics: Area of Application
Figure 4.11 Exosome Therapeutics: Distribution by Type of Therapy
Figure 4.12 Exosome Therapeutics: Distribution by Dosing Frequency
Figure 4.13 Exosome Therapeutics: Distribution by Type of Therapy (By method of composition)
Figure 4.14 Exosome Therapeutics: Distribution by Line of Treatment
Figure 4.15 Exosome Therapy Developers: Distribution by Year of Establishment
Figure 4.16 Exosome Therapy Developers: Distribution by Company Size
Figure 4.17 Exosome Therapy Developers: Distribution by Location of Headquarters
Figure 4.18 Exosome Therapy Developers: Most Active Players: Distribution by Number of Therapeutic Programs
Figure 6.1 Cellular Biomedicine Group: Financial Information, FY 2015- FY 2019 (USD Million)
Figure 6.2 ReNeuron: Financial Information, FY 2018- FY 2022 (USD Million)
Figure 7.1 Clinical Trials Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year, Pre- 2015- 2022
Figure 7.3 Clinical Trials Analysis: Distribution by Sponsor / Collaborator
Figure 7.4 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study, Pre-2015-2022
Figure 7.5 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial, Pre-2015-2022
Figure 7.7 Clinical Trials Analysis: Distribution by Annual Number of Patients Enrolled
Figure 7.6 Clinical Trials Analysis: Distribution by Study Design
Figure 7.9 Clinical Trials Analysis: Distribution by Age Group
Figure 7.10 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
Figure 7.11 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
Figure 7.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 7.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 7.14 Clinical Trials Analysis: Distribution by Trial Location
Figure 7.15 Clinical Trials Analysis: Distribution by Trial Status and Geography
Figure 7.15 Clinical Trials Analysis: Distribution by Trial Status, Patients Enrolled and Geography
Figure 8.1 Academic Grant Analysis: Year-wise Distribution of Number of Grants, Pre-2019-2022
Figure 8.2 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded, Pre-2019-2022 (USD Million)
Figure 8.3 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
Figure 8.4 Academic Grant Analysis: Analysis by Type of Funding Institute Center
Figure 8.5 Academic Grant Analysis: Distribution by Support Period
Figure 8.6 Academic Grant Analysis: Distribution by Purpose of Grants
Figure 8.7 Academic Grant Analysis: Distribution by Emerging Focus Area
Figure 8.8 Academic Grant Analysis: Distribution by Grant Activity Code
Figure 8.9 Academic Grant Analysis: Distribution by Location of Recipients Organizations
Figure 8.10 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number of Grants
Figure 8.11 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount Awarded
Figure 8.12 Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.13 Academic Grant Analysis: Distribution by Study Section
Figure 8.14 Academic Grant Analysis: Distribution by Type of Grant Application
Figure 8.15 Academic Grant Analysis: Analysis by Funding Institute Center and Support Year
Figure 9.1 Global Events: Cumulative Half Yearly Trend, 2019-2022
Figure 9.2 Global Events: Distribution by Event Platform
Figure 9.3 Global Events: Distribution by Type of Event
Figure 9.4 Global Events: Distribution by Region
Figure 9.6 Most Active Organizers: Distribution by Number of Events
Figure 9.7 Most Active Speakers: Distribution by Number of Events
Figure 9.8 Most Active Industry Participants: Distribution by Number of Events
Figure 9.9 Most Active Non-Industry Participants: Distribution by Number of Events
Figure 9.10 Global Events: Distribution by Designation of Participant
Figure 9.11 Global Events: Distribution by Affiliated Department of Participant
Figure 9.12 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, 2017- 2022
Figure 10.4 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, 2017- 2022
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Technology Platform
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.7 Word Cloud Analysis: Emerging Focus Areas
Figure 10.8 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Figure 10.9 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.10 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 10.11 Partnerships and Collaborations: Regional Distribution of Partnerships
Figure 10.12 Partnerships and Collaborations: Distribution by Geography
Figure 11.1 Funding and Investments: Year-wise Distribution by Year of Funding, 2017- 2022
Figure 11.2 Funding and Investments: Year-wise Distribution by Amount Invested, 2017- 2022 (USD Million)
Figure 11.3 Funding and Investments: Distribution by Type of Funding
Figure 11.4 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, 2017- 2022
Figure 11.5 Funding and Investments: Distribution by Purpose of Funding
Figure 11.6 Funding and Investments: Distribution by Target Disease Indication(s)
Figure 11.7 Funding and Investments: Distribution by Therapeutic Area
Figure 11.8 Most Active Players: Distribution by Number of Funding Instances
Figure 11.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 11.10 Key Investors: Distribution by Number of Funding Instances
Figure 11.11 Funding and Investments: Distribution by Geography
Figure 11.12 Summary of Funding Instances
Figure 12.1 Start-up Health Indexing: Distribution by Pipeline Strength
Figure 12.2 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 12.2 Start-up Health Indexing: Distribution by Indication Diversity
Figure 12.5 Start-up Health Indexing: Distribution by Number of Partnerships
Figure 12.3 Start-up Health Indexing: Distribution by Financial Support
Figure 12.4 Start-up Health Indexing: Distribution by Number of Investors
Figure 12.6 Start-up Health Indexing: Roots Analysis Perspective
Figure 12.7 Most Active Start-ups
Figure 13.1 Case Study: Distribution of Exosome Development and Manufacturing Companies by Year of Establishment
Figure 13.2 Case Study: Distribution of Exosome Development and Manufacturing Companies by Company Size
Figure 13.3 Case Study: Distribution of Exosome Development and Manufacturing Companies by Location of Headquarters
Figure 13.4 Case Study: Distribution of Exosome Development and Manufacturing Companies by Location of Headquarters and Company Size
Figure 13.5 Case Study: Distribution of Exosome Development and Manufacturing Companies by Type of Service(s) Offered
Figure 13.6 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Isolation
Figure 13.7 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Purification
Figure 13.8 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Characterization
Figure 13.9 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Manufacturing
Figure 13.10 Case Study: Distribution of Exosome Development and Manufacturing Companies by Scale of Operation
Figure 13.11 Case Study: Distribution of Exosome Development and Manufacturing Companies by Scalability
Figure 14.1 Drug Failure Analysis: Distribution by Trial Start and Discontinuation Year
Figure 14.2 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
Figure 14.3 Drug Failure Analysis: Distribution by Target Disease Indication(s)
Figure 14.4 Drug Failure Analysis: Distribution by Route of Administration
Figure 14.5 Drug Failure Analysis: Distribution by Type of Sponsor
Figure 14.6 Drug Failure Analysis: Distribution by Reasons for Drug Failure
Figure 15.1 Global Exosome Therapy Market, 2029-2040 (USD Million)
Figure 15.2 Exosome Therapy Market for Allogeneic Therapy, 2029-240 (USD Million)
Figure 15.3 Exosome Therapy Market for Autologous Therapy, 2029-2040 (USD Million)
Figure 15.4 Exosome Therapy Market for Retinitis Pigmentosa, 2031-2040 (USD Million)
Figure 15.5 Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
Figure 15.6 Exosome Therapy Market for Degenerative Meniscal Injury, 2029-2040 (USD Million)
Figure 15.7 Exosome Therapy Market for Fistula Perianal, 2029-2040 (USD Million)
Figure 15.8 Exosome Therapy Market for Dermatological Disorders, 2030-2040 (USD Million)
Figure 15.9 Exosome Therapy Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
Figure 15.10 Exosome Therapy Market for Ophthalmic Disorders, 2029-2040 (USD Million)
Figure 15.11 Exosome Therapy Market for Rectal Disorders, 2029-2040 (USD Million)
Figure 15.12 Fistula Tract Exosome Therapy Market, 2029-2040 (USD Million)
Figure 15.13 Intra-articular Exosome Therapy Market, 2031-2040 (USD Million)
Figure 15.14 Intra-ocular Exosome Therapy Market, 2029-2040 (USD Million)
Figure 15.15 Exosome Therapy Market Geographical Distribution, 2031-2040 (USD Million)
Figure 15.16 Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million)
Figure 15.17 Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
Figure 15.18 AGLE-102: Sales Forecast, 2030-2040 (USD Million)
Figure 15.19 Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million)
Figure 15.20 ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million)
Table 4.1 Exosome Therapeutics: Development Pipeline
Table 4.2 Exosome Therapeutics: List of Developers
Table 5.1 Codiak BioSciences: Product Portfolio
Table 5.2 Codiak BioSciences: Clinical Trial Information
Table 5.3 Recent Developments and Future Outlook
Table 5.4 Coya Therapeutics: Product Portfolio
Table 5.5 Recent Developments and Future Outlook
Table 5.6 Curexsys: Product Portfolio
Table 5.7 Recent Developments and Future Outlook
Table 5.8 EV Therapeutics: Product Portfolio
Table 5.9 Recent Developments and Future Outlook
Table 5.10 Evox Therapeutics: Product Portfolio
Table 5.11 Recent Developments and Future Outlook
Table 5.12 SHIFTBIO: Product Portfolio
Table 5.13 Recent Developments and Future Outlook
Table 6.1 AGLE-102: Product Portfolio
Table 6.2 AGLE-102: Clinical Trial Information
Table 6.1 Ardoxso: Product Portfolio
Table 6.2 Ardoxso: Clinical Trial Information
Table 6.3 Recent Developments and Future Outlook
Table 6.1 haMPC-Exos: Product Portfolio
Table 6.2 haMPC-Exos: Clinical Trial Information
Table 6.3 hMSC-Exos: Product Portfolio
Table 6.4 hMSC-Exos: Clinical Trial Information
Table 6.5 Undisclosed Drug 1: Product Portfolio
Table 6.6 Undisclosed Drug 1: Clinical Trial Information
Table 6.7 Recent Developments and Future Outlook
Table 6.1 CovenD24: Product Portfolio
Table 6.2 CovenD24: Clinical Trial Information
Table 6.1 Undisclosed Drug 1: Product Portfolio
Table 6.2 Undisclosed Drug 1: Clinical Trial Information
Table 6.1 Recent Developments and Future Outlook
Table 6.2 Undisclosed Drug 1: Product Portfolio
Table 7.1 Exosome Therapeutics: List of Clinical Trials, 2017-2022
Table 8.1 Exosome Therapeutics: List of Grants Awarded, Pre-2015-2022
Table 9.1 Exosome Therapeutics: List of Global Events, 2017-2022
Table 10.1 Exosome Therapeutics: List of Partnerships and Collaborations, 2017-2022
Table 11.1 Exosome Therapeutics: List of Funding and Investment, 2017-2022
Table 12.1 Exosome Therapeutics: List of Start-Ups, 2017-2022
Table 13.1 Case Study: List of Exosome Service Providers
Table 17.1 Exosome Therapy Market: Distribution by Phase of Development
Table 17.2 Exosome Therapy Market: Distribution by Technology Platform
Table 17.3 Exosome Therapy Market: Distribution by Derived Source
Table 17.4 Exosome Therapy Market: Distribution by Target Disease Indication(s)
Table 17.5 Exosome Therapy Market: Distribution by Therapeutic Area
Table 17.6 Exosome Therapy Market: Distribution by Route of Administration
Table 17.7 Exosome Therapy Market: Area of Application
Table 17.8 Exosome Therapy Market: Distribution by Type of Therapy
Table 17.9 Exosome Therapy Market: Distribution by Dosing Frequency
Table 17.10 Exosome Therapy Market: Distribution by Type of Therapy (By method of composition)
Table 17.11 Exosome Therapy Market: Distribution by Line of Treatment
Table 17.12 Exosome Therapeutics Developers: Distribution by Year of Establishment
Table 17.13 Exosome Therapeutics Developers: Distribution by Company Size
Table 17.14 Exosome Therapeutics Developers: Distribution by Location of Headquarters
Table 17.15 Exosome Therapeutics Developers: Most Active Players: Distribution by Number of Therapeutic Programs
Table 17.16 Cellular Biomedicine Group: Financial Information, FY 2015- FY 2019 (USD Million)
Table 17.17 ReNeuron: Financial Information, FY 2018- FY 2022 (USD Million)
Table 17.18 Clinical Trials Analysis: Distribution by Trial Status
Table 17.19 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year, Pre- 2015- 2022
Table 17.20 Clinical Trials Analysis: Distribution by Sponsor / Collaborator
Table 17.21 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study, Pre-2015-2022
Table 17.22 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial, Pre-2015-2022
Table 17.23 Clinical Trials Analysis: Distribution by Annual Number of Patients Enrolled
Table 17.24 Clinical Trials Analysis: Distribution by Study Design
Table 17.25 Clinical Trials Analysis: Distribution by Age Group
Table 17.26 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
Table 17.27 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
Table 17.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 17.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 17.30 Clinical Trials Analysis: Distribution by Trial Location
Table 17.31 Clinical Trials Analysis: Distribution by Trial Status and Geography
Table 17.32 Clinical Trials Analysis: Distribution by Trial Status, Patients Enrolled and Geography
Table 17.33 Academic Grant Analysis: Year-wise Distribution of Number of Grants, Pre-2019-2022
Table 17.34 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded, Pre-2019-2022 (USD Million)
Table 17.35 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
Table 17.36 Academic Grant Analysis: Analysis by Type of Funding Institute Center
Table 17.37 Academic Grant Analysis: Distribution by Support Period
Table 17.38 Academic Grant Analysis: Distribution by Purpose of Grants
Table 17.39 Academic Grant Analysis: Distribution by Grant Activity Code
Table 17.40 Academic Grant Analysis: Distribution by Location of Recipients Organizations
Table 17.41 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number
Table 17.42 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount
Table 17.43 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 17.44 Academic Grant Analysis: Distribution by Study Section
Table 17.45 Academic Grant Analysis: Distribution by Type of Grant Application
Table 17.46 Academic Grant Analysis: Analysis by Funding Institute Center and Support
Table 17.47 Global Events: Cumulative Half Yearly Trend, 2019-2022
Table 17.48 Global Events: Distribution by Event Platform
Table 17.49 Global Events: Distribution by Type of Event
Table 17.50 Global Events: Distribution by Region
Table 17.51 Most Active Organizers: Distribution by Number of Events
Table 17.52 Most Active Speakers: Distribution by Number of Events
Table 17.53 Most Active Industry Participants: Distribution by Number of Events
Table 17.54 Most Active Non-Industry Participants: Distribution by Number of Events
Table 17.55 Global Events: Distribution by Designation of Participant
Table 17.56 Global Events: Distribution by Affiliated Department of Participant
Table 17.57 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Table 17.58 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.59 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, 2017- 2022
Table 17.60 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, 2017- 2022
Table 17.61 Partnerships and Collaborations: Distribution by Type of Technology Platform
Table 17.62 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.63 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Table 17.64 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.65 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Table 17.66 Partnerships and Collaborations: Regional Distribution of Partnerships
Table 17.67 Partnerships and Collaborations: Distribution by Geography
Table 17.68 Funding and Investments: Year-wise Distribution by Year of Funding, 2017-2022 (USD Million)
Table 17.69 Funding and Investments: Year-wise Distribution by Amount Invested, 2017- 2022
Table 17.70 Funding and Investments: Distribution by Type of Funding
Table 17.71 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, 2017- 2022
Table 17.72 Funding and Investments: Distribution by Purpose of Funding
Table 17.73 Funding and Investments: Distribution by Target Disease Indication(s)
Table 17.74 Funding and Investments: Distribution by Therapeutic Area
Table 17.75 Most Active Players: Distribution by Number of Funding Instances
Table 17.76 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.77 Key Investors: Distribution by Number of Funding Instances
Table 17.78 Funding and Investments: Distribution by Geography
Table 17.79 Start-up Health Indexing: Distribution by Pipeline Strength
Table 17.80 Start-up Health Indexing: Distribution by Pipeline Maturity
Table 17.81 Start-up Health Indexing: Distribution by Indication Diversity
Table 17.82 Start-up Health Indexing: Distribution by Number of Partnerships
Table 17.83 Start-up Health Indexing: Distribution by Financial Support
Table 17.84 Start-up Health Indexing: Roots Analysis Perspective
Table 17.85 Most Active Start-ups
Table 17.86 Case Study: Distribution of Exosome Development and Manufacturing Companies by Year of Establishment
Table 17.87 Case Study: Distribution of Exosome Development and Manufacturing Companies by Company Size
Table 17.88 Case Study: Distribution of Exosome Development and Manufacturing Companies by Location of Headquarters
Table 17.89 Case Study: Distribution of Exosome Development and Manufacturing Companies by Location of Headquarters and Company Size
Table 17.90 Case Study: Distribution of Exosome Development and Manufacturing Companies by Type of Service(s) Offered
Table 17.91 Case Study: Distribution of Exosome Development and Manufacturing Companiesby Method(s) of Isolation
Table 17.92 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Purification
Table 17.93 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Characterization
Table 17.94 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Manufacturing
Table 17.95 Case Study: Distribution of Exosome Development and Manufacturing Companies by Scale of Operation
Table 17.96 Case Study: Distribution of Exosome Development and Manufacturing Companies by Scalability
Table 17.97 Drug Failure Analysis: Distribution by Trial Start and Discontinuation Year
Table 17.98 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
Table 17.99 Drug Failure Analysis: Distribution by Target Disease Indication(s)
Table 17.100 Drug Failure Analysis: Distribution by Route of Administration
Table 17.101 Drug Failure Analysis: Distribution by Type of Sponsor
Table 17.102 Drug Failure Analysis: Distribution by Reasons for Drug Failure
Table 17.103 Global Exosome Therapy Market, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.104 Exosome Therapy Market for Autologous Therapy, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.105 Exosome Therapy Market for Allogeneic Therapy, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.106 Exosome Therapy Market for Degenerative Meniscal Injury, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.107 Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.108 Exosome Therapy Market for Fistula Perianal, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.109 Exosome Therapy Market for Retinitis Pigmentosa, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.110 Exosome Therapy Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.111 Exosome Therapy Market for Muscoskeletal Disorders, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.112 Exosome Therapy Market for Ophthalmic Disorders, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.113 Exosome Therapy Market for Rectal Disorders, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.114 Fistula Tract Exosome Therapy Market, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.115 Intra-articular Exosome Therapy Market, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.116 Intra-ocular Exosome Therapy Market, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.117 Exosome Therapy Market Geographical Distribution, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.118 Erciyes University’s Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.119 Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.120 AGLE-102: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.121 Trehan University of Medical Sciences’ Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.122 ReNeuron’ Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report:
Source 1: https://conciergemdla.com/blog/benefits-and-risks-of-exosome-therapy
Source 2: https://pubmed.ncbi.nlm.nih.gov/32697573/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES